PETRA RIETSCHEL, M.D., Ph.D.                 

 click to view this physician's blog

Click here for full CV

EXPERTISE: Sarcomas

Director of Sarcoma Oncology at Albert Einstein Cancer Center

SPECIAL ACCOMPLISHMENTS:

  • Director Melanoma/Sarcoma Medical Oncology
  • Clinical Program Director Melanoma/Sarcoma
  • Member Breast Medical Oncology Division
  • Assistant Professor of Medicine at the Albert - Einstein University

PROFESSIONAL EDUCATION & TRAINING:

Oncology/Hematology Fellowship: Memorial-Sloan-Kettering Cancer Center

Research Fellowship: Massachusetts General Hospital, Department of Neuroendocrinology 

 

Residency: Internal Medicine, Massachusetts General Hospital, Harvard Medical School

Medical School: M.D. University of Heidelberg, Germany,

                           Ph.D. University of Heidelberg, Germany

POSTDOCTORAL EDUCATION:

  • Memorial Sloan-Kettering Cancer Center Human Subjects Research Training Course
  • Memorial Sloan-Kettering Cancer Center Clinical Research Methodology Course
  • Rockefeller University Tri-Institutional Ethics in Research Course
  • Memorial Sloan-Kettering Cancer Center Biostatistics Course
  • New York Blood Bank Course

BOARD CERTIFICATIONS:

  • Diplomat of Internal Medicine
  • Diplomat of Medical Oncology
  • Diplomat of Hematology

CURRENT POSITIONS:

  • Montefiore Medical Center
  • Albert Einstein College of Medicine
  • Montefiore Einstein Cancer Center

 

PREVIOUS POSITIONS & APPOINTMENTS:

Associate Professor, Dept of Medicine, Hematology/Oncology, Creighton University

 

PROFESSIONAL ACTIVITIES, MEMBERSHIPS, & ACCOMPLISHMENTS:

  • American Medical Association
  • American College of Physicians
  • Massachusetts Medical Society
  • American Society of Clinical Oncology
  • American Society of Hematology
  • American Association for Cancer Research
  • New York Metropolitan Breast Cancer Group
  • Connective Tissue Society
  • New York Melanoma Consortium

RESEARCH:

Breast:

Principle Investigator for the following trials:

  • Randomized Phase II Trial of ABT-888 vs. ABT-888 in Combination with Carboplatin in Patients with Stage IV BRCA- associated Breast Cancer, NCI#8264- Pending
  •  CDX011-03-A Phase II, Randomized, Multicenter Study of C DX-011 (CR011-vcMMAE) in Patients with Advanced GPNMB- expressing Breast Cancer-Pending
  • Phase-I-II Trial of Vorinstat plus Weekly Paclitaxel (+/- Trastuzumab) followed by Doxorubicin - Cyclophosphamide in Patients With Locally Advanced Breast Cancer (HER-positivie or "triple-negative), NYCC1- Accrual almost completed
  • Co-investigator for all other Breast trials

Sarcoma:

 

Local Principle Investigator for the following trials:

  • Phase II Study. Temsirolimus & IGF-1 Receptor Antibody IMC-A2 in Patients with Metastatic Sarcomas- Approved, 5 patients enrolled (MSKCC)
  • A randomized controlled study of Yondelis (Trabectedin) or Darcarbazine for the treatment of advanced liposarcoma or leiomyosarcoma previously treated with and anthracycline and ifosfamide (Johnson and Johnson)
  • A phase III multicenter, international, randomized, double blinded placebo controlled study of doxorubicin plus Palifosfamide compared to doxorubicin plus placebo in patients with front line metastatic soft tissue sarcoma.
  • Principle Investigator for SARC

Melanoma:

  • E2607, A Phase II trial of Dasatinib in Patients with Unresectable Locally Advanced or Stage IV Mucosal, Acral and Solar Melanomas.
  • A pilot trial to evaluate the molecular effects of RO4929097 as neoadjuvant therapy for resectable Stage IIIB, IIIC or IV melanoma, Ph II 8531
  • A multicenter treatment protocol for Expanded Access use of Ipilimumab (BMS-734016) Monotherapy in subjects with unresectable stage III or stage IV
  • A Phase I-II Study of Combination Oral CC-5013 Lenalidomide, Oral Sunitinib and Low Dose Oral Metronomic Cyclophosphamide for the Treatment of Stage IV Cutaneous and Ocular Melanoma.